Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIRTIVITY-ON: Long-term Safety and Efficacy of Verducatib in Bronchiectasis
NCT07915219Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2027
- Primary completion
- Jul 2029
- Countries
- 39
01
Overview
A Phase 3 trial of verducatib in bronchiectasis, sponsored by Boehringer Ingelheim. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT07915219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07915219.